Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Intuitive Surgical, Inc. (ISRG), MAKO Surgical Corp. (MAKO): Is This Health Care Stock Too Risky to Buy?

The past year has been extremely volatile for Intuitive Surgical, Inc. (NASDAQ:ISRG), a stock once beloved by Wall Street and investors for its habit of producing strong growth quarter after quarter.

Recently, though, the company has been plagued by widespread concerns over the safety of its da Vinci surgical robots. These concerns transformed into panic when the Food and Drug Administration issued a warning to the company after inspections conducted in April and May revealed possible links to deaths.

Should investors avoid the stock at all costs? Or is the recent drop in stock price nothing more than a unique buying opportunity?

Storm clouds gathering
In light of the increased scrutiny, investors were warned that the second quarter, and perhaps the remainder of the year, would be difficult. These fears were realized when Intuitive Surgical, Inc. (NASDAQ:ISRG) posted weak second-quarter results, which showed that revenue clocked in at $578 million and earnings per share missed analyst expectations.

Intuitive Surgical, Inc. (NASDAQ:ISRG)It’s important to consider that even in an extremely difficult period, Intuitive Surgical, Inc. (NASDAQ:ISRG) still posted quarterly growth in both metrics. However, the results broke a four-year streak of double-digit quarter growth, and the market was clearly unimpressed.

For investors who’d rather not accept Intuitive Surgical, Inc. (NASDAQ:ISRG)’s heightened level of headline risk, there aren’t that many competitors to choose from. That’s actually one of the merits of Intuitive Surgical’s buy case; its da Vinci robots are a truly revolutionary, one-of-a-kind technology. The closest competitor to Intuitive Surgical is MAKO Surgical Corp. (NASDAQ:MAKO), which also produces robotic devices, specifically designed for the knee and hip.

It should be stated that MAKO Surgical Corp. (NASDAQ:MAKO) is a much more speculative bet than Intuitive Surgical, Inc. (NASDAQ:ISRG), due to its much smaller size and volatile results. MAKO holds a market cap of just $780 million and has not proven to be consistently profitable in recent years.

MAKO Surgical Corp. (NASDAQ:MAKO) reported net losses every fiscal year between 2008 and 2012. The current year hasn’t seen business conditions improve much. Although MAKO is reporting strong revenue growth — 22% through the first half of the year to be exact — the company’s net loss expanded. MAKO reported a net loss of $0.48 per share through the first half of 2012, and a net loss of $0.63 per share through the first six months of 2013.

As a result, due to MAKO Surgical Corp. (NASDAQ:MAKO)’s questionable fundamentals and inability to turn a profit, investors aren’t exactly getting a suitable alternative to Intuitive Surgical, Inc. (NASDAQ:ISRG).

Of course, within the health care industry there are many stocks to choose from, and investors who still want entry into the medical devices space should consider Johnson & Johnson (NYSE:JNJ).

J&J is a good alternative to Intuitive Surgical, Inc. (NASDAQ:ISRG) because, although it’s also a company heavily involved in medical devices, it offers a vastly different investing proposition. J&J is much more of a slow-and-steady type than Intuitive Surgical.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.